Company intelligence / Profile preview

Meissa Vaccines

Redwood City (previously South San Francisco), California, United Statesmeissavaccines.com ↗

Ownership: Private
Employees: ~50
Development stage: Phase 2

Overview

Meissa's intranasal pediatric RSV vaccine candidate (MV-012-968) demonstrated high immunogenicity with an outstanding safety profile in a Phase 1c study in RSV seronegative infants and young children. All RSV-naïve infants and toddlers demonstrated a vaccine response to the highest dose tested. For their COVID-19 vaccine candidate, early clinical data showed the highest dose triggered similar nasal antibody levels to natural immunity[3][6].

Therapeutic areas: Infectious Diseases
Modalities: Live attenuated vaccines
Industry: Biotech

Drug pipeline

2 assets

MV-012-968

1 more asset in the full pipeline.

Request access →

Partnerships

Exothera S.A. (manufacturing agreement)

Beyond the preview

Go deeper on Meissa Vaccines.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Meissa Vaccines.

Explore the full profile